Currently, various clinical trials in phases I/II or also III have been evaluating CTLA-4 targeted antibodies, including Ipilimumab and Tremelimumab, in different CRC subtypes, some of which have reported promising primary results. This evidence concerns the gene CTLA4 and colorectal carcinoma.